Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized single-blind trial of intratumoral YH01 in previously treated unresectable locally advanced or metastatic head and neck malignancies
ChiCTR2600133618Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Mar 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of YH01 in head and neck cancer (HNC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective response rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
YH01
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR2600133618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133618.